The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials
Autor: | Heiner K. Berthold, Armin Zittermann, Stefan Pilz |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Fibroblast growth factor 23 medicine.medical_specialty Medicine (miscellaneous) 030209 endocrinology & metabolism Review Article Placebo group Gastroenterology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Vitamin D and neurology Humans Vitamin D Randomized Controlled Trials as Topic Kidney 030109 nutrition & dietetics Nutrition and Dietetics business.industry Endocrine system and metabolic diseases Vitamins medicine.disease Fibroblast Growth Factors Fibroblast Growth Factor-23 Cardiovascular diseases medicine.anatomical_structure Meta-analysis Heart failure Dietary Supplements business Biomarkers Hormone |
Zdroj: | European Journal of Clinical Nutrition |
ISSN: | 1476-5640 0954-3007 |
DOI: | 10.1038/s41430-020-00725-0 |
Popis: | The phosphaturic hormone fibroblast growth factor 23 (FGF23) is a risk marker of cardiovascular and all-cause mortality. We therefore aimed to synthesize the evidence for the effect of vitamin D administration on circulating FGF23 concentrations. We performed a systematic review and meta-analysis of randomized, placebo-controlled trials (RCTs) in several databases from inception to January 2020. A total of 73 records were identified for full-text review, and 21 articles with 23 studies were included in the final analysis. The selected studies included 1925 participants with 8–156 weeks of follow-up. The weighted mean difference in FGF23 in the vitamin D versus placebo group was +21 pg/ml (95% CI: 13–28 pg/ml; P I2 = 99%). The FGF23 increment was higher in patients with end-stage kidney/heart failure than in other individuals (+300 pg/ml [95% CI: 41–558 pg/ml] vs. +20 pg/ml [95% CI: 12–28 pg/ml], Pinteraction = 0.03), and if baseline 25-hydroxyvitamin D concentrations were Pinteraction = 0.002). Moreover, the FGF23 increment was influenced by vitamin D dose/type (vitamin D dose equivalent ≤ 2000 IU/day: +2 pg/ml [95% CI: 0–3 pg/ml]; vitamin D dose equivalent > 2000 IU/day: +18 pg/ml [95% CI: 6–30 pg/ml]; administration of activated vitamin D: +67 pg/ml [95% CI: 16–117 pg/ml]; Pinteraction = 0.001). Results were not significantly influenced by study duration (Pinteraction = 0.14), age class (Pinteraction = 0.09), or assay provider (Pinteraction = 0.11). In conclusion, this meta-analysis of RCTs demonstrates that vitamin D administration of >2000 IU/d vitamin D or activated vitamin D significantly increased concentrations of the cardiovascular risk marker FGF23, especially in patients with end-stage kidney/heart failure. |
Databáze: | OpenAIRE |
Externí odkaz: |